Pfizer Inc. (NYSE:PFE)

Current assets exhibited a fluctuating pattern over the five-year period. Initially, a decrease is observed from 2021 to 2022, followed by a further decline through 2023. A subsequent increase occurred between 2023 and 2024, but this was partially offset by a decrease in the final year presented, 2025.

Adjusted current assets mirrored this general trend, though the magnitude of change differed slightly. The largest decrease occurred between 2021 and 2022, similar to the trend in reported current assets. The increase from 2023 to 2024 was also present in the adjusted figures, and a decrease is noted in 2025.

Overall Trend

Both current assets and adjusted current assets demonstrate a general decline from 2021 to 2025, despite intermediate increases. The adjusted figures consistently remain slightly above the reported current asset values throughout the period.

Magnitude of Change

The most substantial decrease in both metrics occurred during the 2021-2022 timeframe, with a reduction of approximately 8.4 billion US dollars for current assets and 8.5 billion US dollars for adjusted current assets. The increase from 2023 to 2024 was less pronounced, at roughly 7 billion US dollars for both metrics.

Difference Between Metrics

The difference between current assets and adjusted current assets remains relatively stable across the years, generally ranging between 500 and 600 million US dollars. This suggests that the adjustments being made are consistent in their impact on the reported value of current assets.

The fluctuations observed may warrant further investigation to understand the underlying drivers, such as changes in inventory levels, accounts receivable, or the application of specific accounting adjustments. The consistent difference between the two metrics suggests a systematic adjustment process is in place.

Total assets exhibited a general increasing trend from 2021 to 2023, followed by declines in the subsequent two years. A comparison of reported total assets with adjusted total assets reveals consistent differences across the observed period, suggesting the presence of adjustments impacting the reported value of assets.

Overall Trend in Total Assets

Total assets increased from US$181,476 million in 2021 to US$226,501 million in 2023, representing a cumulative growth of approximately 24.8%. However, this was followed by a decrease to US$213,396 million in 2024 and further to US$208,160 million in 2025, indicating a contraction of approximately 8.1% from the 2023 peak.

Adjusted Total Assets Trend

Adjusted total assets mirrored the trend of total assets, increasing from US$180,350 million in 2021 to US$225,203 million in 2023, a growth of roughly 24.9%. Similar to total assets, adjusted total assets then decreased to US$207,261 million in 2024 and US$201,153 million in 2025, representing a decline of approximately 10.7% from the 2023 high.

Difference Between Total and Adjusted Assets

The difference between total assets and adjusted total assets remained relatively stable across the period, generally ranging between US$1,126 million and US$2,302 million. This suggests a consistent application of the adjustment methodology. In 2021, the difference was US$1,126 million. In 2022, it was US$4,320 million. In 2023, it was US$1,300 million. In 2024, it was US$6,135 million. In 2025, it was US$7,007 million. The increasing difference in 2024 and 2025 warrants further investigation to understand the nature of the adjustments.

Percentage Change Analysis

The percentage change in adjusted total assets from 2021 to 2022 was approximately 7.0%. From 2022 to 2023, the increase was approximately 16.7%. The percentage decrease from 2023 to 2024 was approximately 8.4%, and from 2024 to 2025, it was approximately 3.0%. The rate of increase slowed from 2022 to 2023, while the rate of decrease accelerated from 2023 to 2024.

Current liabilities exhibited fluctuations over the five-year period. Initially, a slight decrease is noted from 2021 to 2022, followed by a substantial increase in 2023. Subsequent years demonstrate a decline, with 2024 showing a moderate reduction and 2025 experiencing the most significant decrease.

Overall Trend

The overall trend in current liabilities is characterized by volatility. While a general downward trajectory is apparent from the peak in 2023 to the end of the period, the interim increases and decreases suggest underlying shifts in short-term obligations.

Adjusted Current Liabilities

Adjusted current liabilities mirrored the trend observed in the unadjusted figures. A decrease occurred between 2021 and 2022, followed by a considerable rise in 2023. The subsequent years, 2024 and 2025, both showed declines, with the decrease in 2025 being more pronounced.

Relationship between Current and Adjusted Liabilities

The difference between current liabilities and adjusted current liabilities remained relatively consistent throughout the period, suggesting that the adjustments applied were systematic and did not dramatically alter the overall magnitude of short-term obligations. The adjustments reduced the reported current liabilities by approximately US$816 million in 2021, US$991 million in 2022, US$1325 million in 2023, US$1683 million in 2024, and US$1444 million in 2025.

The substantial increase in both current and adjusted liabilities in 2023 warrants further investigation to understand the specific factors driving this change. The declines observed in 2024 and 2025 could indicate successful management of short-term debt or other obligations.

Total liabilities exhibited volatility over the five-year period. Initially decreasing from 2021 to 2022, they increased substantially in 2023 before declining again in 2024 and 2025. Adjusted total liabilities mirrored this pattern, though the magnitude of change was slightly less pronounced.

Overall Trend

From 2021 to 2025, total liabilities decreased overall from US$104,013 million to US$121,385 million. However, this decrease was not linear. A significant increase occurred between 2022 and 2023, suggesting a substantial event or series of events impacting the company’s obligations during that period. The subsequent declines in 2024 and 2025 indicate a reversal of this trend.

Year-over-Year Changes

A decrease of US$2,725 million in total liabilities was observed from 2021 to 2022. This was followed by a considerable increase of US$35,925 million from 2022 to 2023. The period from 2023 to 2024 saw a decrease of US$12,314 million, and a further decrease of US$3,514 million occurred from 2024 to 2025.

Adjusted Liabilities vs. Total Liabilities

The difference between total liabilities and adjusted total liabilities remained relatively consistent throughout the period, ranging from approximately US$1,420 million to US$2,628 million. This suggests that the adjustments applied are systematic and do not represent large, isolated corrections. The adjustments consistently result in a lower reported liability figure.

The fluctuations in total liabilities warrant further investigation to understand the underlying drivers. The substantial increase in 2023, followed by subsequent declines, could be related to debt financing, acquisitions, or changes in accounting standards. The consistent application of adjustments suggests a recurring refinement of the reported liability position.

Total shareholders’ equity exhibited an initial increase followed by a subsequent decline over the five-year period. Reported total equity increased from US$77,201 million in 2021 to US$95,661 million in 2022, representing a substantial gain. However, from 2022 onward, a consistent downward trend is observed, with equity decreasing to US$86,476 million by 2025.

Equity Trend – Reported vs. Adjusted

The adjusted total equity figures generally mirror the trend of the reported total shareholders’ equity. An increase is noted from US$77,756 million in 2021 to US$93,823 million in 2022, followed by a decline to US$84,079 million in 2025. The magnitude of the decline appears slightly more pronounced in the adjusted equity figures compared to the reported equity.

The difference between reported and adjusted equity remains relatively stable throughout the period, fluctuating between approximately US$500 million and US$1,800 million. This suggests that the adjustments made to stockholders’ equity are consistent in their impact, but do contribute to a different equity valuation than the initially reported figures. The consistent negative adjustment implies a recurring item or set of items reducing the reported equity value.

Percentage Change – Total Equity

From 2021 to 2022, total shareholders’ equity increased by approximately 23.9%. However, from 2022 to 2025, it decreased by approximately 9.6%. This indicates a significant shift from growth to contraction in equity value during the latter part of the period.

The consistent decline in both reported and adjusted equity from 2022 to 2025 warrants further investigation to determine the underlying causes. Potential factors could include share repurchases, dividend payments, losses incurred, or other accounting adjustments impacting retained earnings. The relatively stable difference between the reported and adjusted values suggests the adjustments are not the primary driver of the overall downward trend, but rather a consistent component of the equity calculation.

An examination of the financial information reveals trends in reported and adjusted capital structures over a five-year period. Total reported debt increased significantly from 2021 to 2023, then decreased modestly in the subsequent two years. Total shareholders’ equity exhibited growth from 2021 to 2022, followed by a decline through 2025. Total reported capital mirrored the debt trend, increasing to 2023 and then decreasing slightly.

Debt Trends

Total reported debt began at US$38,436 million in 2021, decreased to US$35,829 million in 2022, and then rose substantially to US$71,888 million in 2023. A subsequent decrease to US$64,351 million in 2024 and a further slight decrease to US$64,795 million in 2025 were observed. Adjusted total debt followed a similar pattern, starting at US$41,395 million in 2021, decreasing to US$39,046 million in 2022, increasing to US$75,041 million in 2023, and then decreasing to US$66,993 million in 2024 and US$67,416 million in 2025. The adjusted debt figures are consistently higher than the reported debt figures throughout the period.

Equity Trends

Total Pfizer Inc. shareholders’ equity increased from US$77,201 million in 2021 to US$95,661 million in 2022, before declining to US$89,014 million in 2023, US$88,203 million in 2024, and US$86,476 million in 2025. Adjusted total equity mirrored this trend, beginning at US$77,756 million in 2021, rising to US$93,823 million in 2022, and then decreasing to US$90,618 million in 2023, US$86,604 million in 2024, and US$84,079 million in 2025. The difference between reported and adjusted equity remains relatively stable across the observed period.

Capital Trends

Total reported capital increased from US$115,637 million in 2021 to US$131,490 million in 2022, peaked at US$160,902 million in 2023, and then decreased to US$152,554 million in 2024 and US$151,271 million in 2025. Adjusted total capital exhibited a similar trajectory, starting at US$119,151 million in 2021, increasing to US$132,869 million in 2022, reaching US$165,659 million in 2023, and then decreasing to US$153,597 million in 2024 and US$151,495 million in 2025. The adjusted capital figures are consistently higher than the reported capital figures.

The adjustments to debt and equity consistently result in higher total capital figures. The most significant changes occur between 2022 and 2023, with substantial increases in both reported and adjusted debt and capital, coupled with a smaller increase in equity. The period from 2023 to 2025 shows a moderate decline in both reported and adjusted capital, primarily driven by decreases in debt.

Net income attributable to Pfizer Inc. common shareholders demonstrated significant volatility between 2021 and 2025. Reported net income peaked in 2022 at US$31,372 million before experiencing a substantial decline in subsequent years. Adjusted net income before allocation to noncontrolling interests mirrored this trend, though with differing magnitudes and a negative value recorded in 2023.

Net Income Trend

Net income increased notably from US$21,979 million in 2021 to US$31,372 million in 2022, representing a growth of approximately 42.7%. However, 2023 saw a dramatic decrease to US$2,119 million, a decline of roughly 93.2% from the prior year. A partial recovery occurred in 2024, with net income rising to US$8,031 million, followed by a slight decrease to US$7,771 million in 2025. This suggests a period of exceptional performance in 2022 followed by a significant correction and subsequent stabilization at a lower level.

Adjusted Net Income Trend

Adjusted net income followed a similar pattern to reported net income, increasing from US$17,829 million in 2021 to US$25,290 million in 2022, a growth of approximately 42.4%. The most striking observation is the negative adjusted net income of US$-149 million in 2023. This indicates substantial adjustments were made to reported net income, resulting in a loss when considering these modifications. Adjusted net income recovered to US$6,163 million in 2024 and then decreased to US$5,182 million in 2025. The difference between reported and adjusted net income suggests the presence of significant non-recurring items or accounting adjustments impacting the company’s underlying profitability.

Relationship Between Reported and Adjusted Income

The divergence between net income attributable to Pfizer Inc. common shareholders and adjusted net income before allocation to noncontrolling interests widened considerably in 2023. While reported net income remained positive, the adjusted figure turned negative. This suggests that the adjustments made in 2023 were particularly substantial and had a significant impact on the company’s perceived earnings quality. The gap narrowed in 2024 and 2025, but remained notable, indicating ongoing adjustments to reported earnings.

Overall, the period under review demonstrates a volatile earnings landscape. The substantial decline in both reported and adjusted net income in 2023 warrants further investigation to understand the nature and impact of the adjustments made.